Absence of Relationship between Mitochondrial DNA Haplogroups and Cisplatin-Induced Hearing Loss. (3rd July 2017)

• Record Type: Journal Article
• Authors: Graterol, D.; Mir, C.; Garcia-Vaquero, C.; Braña, I.; Pardo, A. N.; Rochera-Villach, M. I.; Lyakhovich, A.; LLeonart, M. E.; Lorente, J.
• Other Names: Rybak Leonard P. Academic Editor.
• Is Part Of: International journal of otolaryngology. Volume 2017(2017)
• Publication Date: 2017-07-03
• Subjects: Otolaryngology -- Periodicals; Otorhinolaryngologic Diseases; Otolaryngology; Electronic journals; Periodicals; Periodicals; 617.51
• DOI: 10.1155/2017/5185268
• Languages: English
• ISSNs: 1687-9201

Abstract

Abstract : Background. Many drugs used for cancer chemotherapy produce reactive oxygen species, thus leading to various complications including nephrotoxicity, cardiotoxicity, and ototoxicity. Objective. We have provided a haplogroup analysis of a cohort of cancer patients treated with chemotherapy and compared factors associated with associated hearing loss. Study Design and Methods. This observational cohort study includes a pure-tone audiometry of the patients who underwent chemotherapeutic treatment. Medical history, presence of risk factors for hearing loss, toxic habits, and association with haplogroups have been determined. Results. 40% of patients developed hearing loss after administration of cisplatin, which was bilateral and symmetrical and of high frequencies. The most frequent haplogroup was H with a slight overexpression of groups V and K and a low frequency of groups J and T. No association of the haplogroup types with the hearing loss has been found; however age was revealed as an important determining factor. Conclusions. Ototoxicity caused by cisplatin is manifested as bilateral, symmetrical, and predominantly high frequency hearing loss. Although we did not find a strong correlation of haplogroups with ototoxicity, our results revealed the existence of a risk group of elderly patients over 60, which are more susceptible to hearing loss induced by cisplatin, than young adults, regardless of preexisting hearing loss.